

Optimal and worst testing strategies for COVID-19

Onishi Tatsuki^{a,b,c}, Honda Naoki^{d,e,f,†}, Yasunobu Igarashi^{g,h,*}

^a Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshidakonoecho, Sakyo, Kyoto, Japan

^b Department of Anesthesiology and Pain Clinic, Juntendo University Shizuoka Hospital, Izunokuni, Shizuoka, Japan

^c Department of Anaesthesiology, Tokyo Metropolitan Bokutoh Hospital, Kotobashi, Sumida, Tokyo, Japan

^d Laboratory for Data-driven Biology, Graduate School of Integrated Sciences for Life, Hiroshima University, Higashihiroshima, Hiroshima, Japan

^e Theoretical Biology Research Group, Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural Sciences, Okazaki, Aichi, Japan

^f Laboratory of Theoretical Biology, Graduate School of Biostudies, Kyoto University, Yoshidakonoecho, Sakyo, Kyoto, Japan

^g E2D3.org, izumi-cho, Kokubunji, Tokyo, Japan

^h Center for Research on Assistive Technology for Building a New Community, Nagoya Institute of Technology, Nagoya, Aichi, Japan

* Corresponding author

Yasunobu Igarashi

Center for Research on Assistive Technology for Building a New Community, Nagoya Institute of Technology

Gokiso-cho, Showa-ku, Nagoya, Aichi, 466-8555 Japan

Tel.: +81-52-735-5334

E-mail: yasunobu.igarashi@gmail.com

† Co-corresponding author

Honda Naoki

Laboratory for Data-driven Biology, Graduate School of Integrated Sciences for Life, Hiroshima University, 1-3-2 Kagamiyama, Higashi-Hiroshima City, Hiroshima, 739-8511 Japan

Tel.: +81-82-424-7336

E-mail: nhonda@hiroshima-u.ac.jp

36 **Abstract**

37 *Background*

38 During the last three years of fighting COVID-19, governments have been seeking optimal solutions to
39 minimize the negative impacts on societies. They actively used mathematical models such as the susceptible,
40 infectious, exposed, recovered, and dead (SEIRD) model to predict the spread of infection. However, in the
41 end, all governments had difficulty figuring out how to adopt testing strategies.

43 *Methods*

44 In this study, we developed a testing-SEIRD model, which incorporates testing strategy and testing
45 characteristics. In this model, people who are tested positive are admitted to the hospital within the capacity
46 and medical resources. Through simulations, we examined the infection spread depending on the balance
47 between follow-up testing and mass testing, which test people closely contacted with infected persons and
48 people with symptoms, respectively.

50 *Results*

51 We showed that there are optimal and worst combinations of the follow-up and mass testing. These
52 strategies are subject to total resources and cost ratio of testing costs. We also found that these combinations
53 provide an all-or-nothing response for whether the spread of infection expands or extinguishes.

55 *Conclusions*

56 While this model alerts us to the existence of a worst testing strategy, it also reveals that an optimal testing
57 strategy can lead to infection containment. Therefore, the testing-SEIRD model is useful in making decisions
58 on testing strategies for the emerging infectious disease outbreaks.

59

60 Introduction

61 Coronavirus disease 2019 (COVID-19) emerged in Wuhan, China as global healthcare concern [1,2]. Due to
62 its high transmission ability via aerosol, and to lack of a specific treatment in the early stage of the COVID-
63 19 Alpha variant pandemic, 5.5 million people have been infected, and 350,000 people have died by April
64 2020 [3]. Medical resource in hospitals is primarily consumed by treatments for COVID-19 patients [1,2].
65 As of April 2020, approximately 10% of hospital beds, or 10-20% of ICU beds are occupied with COVID-19
66 care [3–5]. Moreover, from May 2020, the COVID-19 Beta variant emerged. Every time a new variant of
67 concern (VOC) emerges, such as the Beta, Gamma, Delta and Omicron variant, society requires an update of
68 knowledge about VOC [6–8].

69 To minimize the number of deaths, society should be aware of the advantages and disadvantages of
70 testing for COVID-19 [9]. From a perspective of individuals, testing has advantages so that asymptomatic
71 infected individuals can be detected and prepared for symptomatic treatment, whereas from a perspective of
72 society, testing prevents secondary infections, expecting the reduction of the number of deaths [10–12]. On
73 the other hand, testing has disadvantages especially at the initial pandemic stage as seen in the Alpha variant
74 pandemic in April 2020, in which no specific treatment was established and testing characteristics, i.e.,
75 sensitivity and specificity, are unknown. From a perspective of individuals, the result of testing does not
76 change medical care because of no specific treatment, whereas from a perspective of society, testing is done
77 aimlessly and whether testing results should be trusted was uncertain, resulting in waste of medical and
78 human resources. Therefore, in every early stage of every newly emerging VOC, policymakers should
79 decide the volume of testing with knowledge of the testing characteristics.

80 There was a controversy about the testing policies to minimize the number of deaths in the early
81 stage of the COVID-19 Alpha variant pandemic [7,10,11,13,15–20]. That controversy was between two
82 extreme policies to balance the medical supply and demand: “mass-testing policy” and “no-testing policy”
83 [21]. The mass-testing policy claims that all people must be tested for public health, regardless of the
84 symptoms [22–24]. The mass-testing policy assumes that testing and hospitalization of asymptomatic patient
85 is important to reduce the total number of deaths even in the absence of the specific treatment. Contrary to
86 the mass-testing policy, no-testing policy claims that testing should be limited to symptomatic patient [21].
87 The no-testing policy assumes that asymptomatic patient cannot expect a benefit from mass-testing in the
88 absence of a specific treatment. Although there is discordance in these two policies with different
89 assumptions, these two policies agree with testing on people with symptoms. They disagree on the extent of
90 the asymptomatic population tested.

91 What is the most practical testing policy to minimize the number of deaths? The testing strategies for
92 people without symptoms have two options: follow-up testing-dominant strategy that follows and tests the
93 exposed population and mass-testing-dominant strategy that randomly tests the infected population. There
94 remains a problem that it is uncertain to what extent follow-up testing and mass-testing for asymptomatic

95 populations will affect the number of deaths and lead to the optimal and the worst outcomes especially in
96 early stage of emerging VOC in future [7,10,11,13,15–20].

97 In this paper, we developed a testing-SEIRD model, aiming to evaluate the testing strategy with a
98 mixture of follow-up and mass-testing in terms of minimization of the number of deaths in the early stage of
99 the newly emerging VOC. The testing-SEIRD model took account for testing characteristics, testing
100 strategies, hospitalized subpopulation, and the amount of medical resources [25]. Using this model, we
101 examined the worst and optimal testing strategy in the condition that medical resources are both infinite and
102 finite. We then found that the optimal testing strategy largely depends on the cost ratio of mass-testing and
103 follow-up testing. Thus, this study sheds light on how to minimize the number of deaths in the absence of
104 specific treatment in the early stages of pandemic.

105

106 Model

107 To examine the effect of testing on the infection population dynamics, we developed a new model by
 108 introducing a hospitalised subpopulation, testing strategy, and testing characteristics into the classical SEIRD
 109 model. In general, the SEIRD model is described by the subpopulation dynamics of susceptible, exposed,
 110 infectious, recovered, and dead people (Fig. 1A) as:

$$111 \quad \frac{dS}{dt} = -\frac{bIS}{N}, \quad (2.1)$$

$$112 \quad \frac{dE}{dt} = \frac{bIS}{N} - gE, \quad (2.2)$$

$$113 \quad \frac{dI}{dt} = gE - (r + d)I, \quad (2.3)$$

$$114 \quad \frac{dR}{dt} = rI, \quad (2.4)$$

$$115 \quad \frac{dD}{dt} = dI, \quad (2.5)$$

116 where S , E , I , R , and D indicate the populations of susceptible, exposed, infectious, recovered, and dead
 117 people, respectively. N indicates the total population, that is, $N=S+E+I+R$. b indicates the exposure rate,
 118 which reflects the level of social activity; g , r , and d indicate the transition rates among the subpopulations.
 119 For this model, it is assumed that the recovered populations acquire permanent immunity, indicating that
 120 they will never be infected.

121 Regarding the testing-SEIRD model, we incorporated the testing characteristics and testing strategy
 122 into the classical SEIRD model by dividing the population into outside and inside of the hospitals (Fig. 1B).
 123 The dynamics of the population outside the hospitals are described by:

$$124 \quad \frac{dS_o}{dt} = -\frac{bI_oS_o}{N_o} + uE_o - aS_h, \quad (2.6)$$

$$125 \quad \frac{dE_o}{dt} = -\frac{bI_oS_o}{N_o} - (u + g)E_o - f(1 - Sp)E_oH(C - N_h), \quad (2.7)$$

$$126 \quad \frac{dI_o}{dt} = gE_o - (r_o + d_o)I_o - mSeI_oH(C - N_h), \quad (2.8)$$

$$127 \quad \frac{dR_o}{dt} = r_oI_o, \quad (2.9)$$

$$128 \quad \frac{dD_o}{dt} = d_oI_o, \quad (2.10)$$

129 and those inside hospitals were described by:

$$130 \quad \frac{dS_h}{dt} = -\frac{bI_hS_h}{N_h} + uE_h + aS_h, \quad (2.11)$$

131
$$\frac{dE_h}{dt} = \frac{bI_h S_h}{N_h} - (u + g)E_h + f(1 - Sp)E_o H(C - N_h), \quad (2.12)$$

132
$$\frac{dI_h}{dt} = gE_h - (r_h + d_h)I_h + mSeI_o H(C - N_h), \quad (2.13)$$

133
$$\frac{dR_h}{dt} = r_h I_h, \quad (2.14)$$

134
$$\frac{dD_h}{dt} = d_h I_h, \quad (2.15)$$

135 where X_o and X_h indicate each population outside and inside the hospitals ($X \in \{S, E, I, R, D, N\}$); N_o and N_h
136 indicate the total populations outside and inside hospitals, respectively (i.e., $N_o = S_o + E_o + I_o + R_o + D_o$ and
137 $N_h = S_h + E_h + I_h$); a indicates the rate of discharge of S_h from hospital to the outside; u and g indicate the non-
138 infection and infection rates, respectively; C indicates the capacity of hospitals. We assumed that these
139 parameters are determined by the nature of the disease; thus, they are independent of inside and outside
140 hospitals. r_j and d_j ($j \in \{o, h\}$) indicate the recovery and death rates from infection, respectively, where $r_o < r_h$,
141 and $d_o < d_h$; f and m indicate the rates of follow-up and mass-testing, corresponding to the extent to which
142 health centers follow exposed populations and take-up infected populations having symptoms, respectively;
143 Sp and Se indicate specificity and sensitivity, respectively, as testing characteristics. The model assumed that
144 I contains a fixed proportion of symptomatic and asymptomatic individuals, and that symptomatic infected
145 individuals receive mass-testing. The hospitalization capacity was introduced by the sigmoid function $H(x) =$
146 $1/(1+\exp(-x))$. The parameter values and initial conditions are listed in Table 1 and discussed in the Materials
147 and Methods section.

148

149 Results

150 We first examine the basic behavior of the testing-SEIRD model by simulation as shown in Fig. 2. Similar to
151 the classical SEIRD model, infection largely expanded, and the infectious population (I_h and I_o) transiently
152 increased in response to the occurrence of infectious people. Susceptible populations (S_h and S_o) gradually
153 decreased and shifted into recovered populations (R_h and R_o) through the exposed (E_h and E_o) and infectious
154 (I_h and I_o) states. During this process, the number of dead cells increases gradually as shown in Fig. 2A. The
155 hospitalized population increase, plateau at the capacity of hospitalizations within the period of infection
156 overshoot, and decrease by the hospital discharge (Fig. 2B). The outside population decrease by
157 hospitalizations through testing and switch to a constant decrease, whereas the hospitalized population
158 reaches its capacity and increases by the hospital discharge (Fig. 2B). Moreover, the outside and hospitalized
159 populations are divided into five types of populations (susceptible, exposed, infectious, recovered, and dead)
160 (Fig. 2C and D). Daily reports of positive tests and deaths transiently increase with different peak timings,
161 and the peak of positive tests precedes that of deaths (Fig. 2E). Reproduction numbers (see Materials and
162 Methods) outside hospitals RN_o switch from greater than one to less than one around the peak timing of
163 infectious populations outside (Fig. 2F). On the contrary, reproduction numbers inside hospitals RN_h are less
164 than one. This indicates that the infectious population in hospitals increases owing to supply from the
165 outside; however, it is not because of the infectious spread in hospitals. The testing-SEIRD model
166 recapitulates basic infection dynamics of the total population as observed in the classical SEIRD model (Fig.
167 2A), and enables us to examine the effect of the testing strategy and testing characteristics with different
168 populations inside and outside hospitals.

169 To investigate the impact of hospitalization capacity on infection dynamics, such as daily reports of
170 positive tests, hospitalizations, and deaths, we simulate the testing-SEIRD model with various capacities (Fig.
171 3A to C). We observe that as the capacity increases, the maximum positive tests, maximum hospitalizations,
172 and cumulative deaths linearly decrease, increase, and decrease, respectively, and they all plateau at
173 approximately 30% capacity (Fig. 3D to F). We have also examined their peak timings and have observe that
174 they change nonlinearly, with certain time window ranges (Fig. 3G–I). These results suggest that the change
175 in capacity has a large effect on the level of spread of the disease; nonetheless, it has a small effect on timing.

176 To illustrate the impact of the testing strategy on infectious outcomes, we examined the cumulative
177 deaths, maximum number of positive tests and hospitalizations, varying follow-up and mass-testing rates.
178 The infectious spread shows an all-or-none response depending on the testing strategy (red and blue regions
179 in Fig. 4). Sensitivity analyses confirmed that such a profile was robustly maintained independent of the
180 model parameters (Fig. S1 and S2).

181 The number of cumulative deaths is almost constant with a small amount of both the follow-up and
182 mass-testing (red region in upper panel of Fig. 4A); nonetheless, the combination of follow-up and mass-
183 testing cooperatively suppresses the infectious spread (blue region in the upper panel of Fig. 4A). We also
184 realize that the maximum number of hospitalizations is immediately saturated by either the follow-up or

185 mass-testing because of the limited hospitalization capacity (upper panel in Fig. 4B). The maximum number
186 of positive tests increases more efficiently with the follow-up testing rate compared to the mass-testing rate
187 (upper panel in Fig. 4C).

188 Subsequently, realistic scenarios were considered by adapting the limited resource L . Practically, we
189 cannot freely control the follow-up and mass-testing rates because of the limited medical resource for both
190 the follow-up and mass-testing. Thus, it is necessary to determine the amount of resource allocated to the
191 follow-up and mass-testing. Here, we consider all the possible decisions subject to the limited resource L as:

$$192 \quad L = c_f f + c_m m, \quad (3.1)$$

193 where c_f and c_m indicate the costs for follow-up and mass-testing, respectively; f and m are reflected by the
194 decisions on how much follow-up and mass-testing are conducted. Considering different L , c_f , and c_m , based
195 on the disease, economic and technological situations of each country, we depicted three lines. The three
196 colored lines in the heat maps correspond to a cost ratio of 1:10, 1:5, and 1:1 for follow-up and mass-testing,
197 respectively (Fig. 4). Given the total amount of resources, we can choose the optimal testing strategy on the
198 line represented by the equation (3.1). We observe that the worst decisions (i.e., the choice of f and m)
199 drastically varied depending on the situation (lower panels of Fig. 4).

200 Regarding the high resource and low ratio of the cost of follow-up testing to that of the mass-testing
201 cost, the number of cumulative deaths abruptly increases as the resource fraction of mass-testing exceeds
202 90% (green line in Fig. 4A). This indicates that the mass-testing dominant testing is the worst strategy for
203 minimizing the cumulative deaths. On the other hand, considering low resource and high ratio of follow-up
204 cost to mass-testing cost, the number of cumulative deaths abruptly decreases at the resource fraction of 20%
205 to 30 % (blue line in Fig. 4A) assigned to mass-testing. Contrary to the previous case, this result suggests
206 that follow-up-dominant testing is the worst strategy. Regarding the intermediate situation between the two
207 cases above, the simulation showed a U-shape with the resource fraction assigned to mass-testing ranging
208 from approximately 10 to 80 % (orange line in Fig. 4A). These results clearly suggested that both follow-up
209 and mass-dominant testing are strategies to avoid, whereas the optimal strategy is a combination of the
210 follow-up and mass-testing. The choice of f and m also changed in the profiles of maximum hospitalizations
211 and positive reports (Fig. 4B and C). Taken together, the optimal strategy for each country/region should be
212 sought with the resource considered.

213 Moreover, we examined how the three variables (i.e., the number of cumulative deaths,
214 hospitalizations, and positive tests) are affected by the testing characteristics (i.e., sensitivity and specificity).
215 We conducted sensitivity analyses for Se and Sp with values from zero to four with 0.01 increments. We
216 obtained almost the same heatmaps in the sensitivity-specificity space although the heatmaps were inverted
217 along the x-axis (Fig. 5). The equations (2.7, 2.8, 2.12, and 2.13) reveal that sensitivity and one-specificity
218 essentially play the same roles in the follow-up and mass-testing. The sensitivity and specificity of the test
219 are not modifiable, whereas the testing strategy can be arbitrary. If the sensitivity is low, an increase in the
220 mass-testing rate can lead to the same infectious result with high sensitivity. On the contrary, if the
221 specificity is low, a decrease in the follow-up testing rate can lead to the same infectious result with high

222 specificity. Therefore, we must manage the optimal testing strategy based on the unmodifiable testing
223 sensitivity and specificity.

224 We have investigated how the infection is expanded based on the testing strategy. However, this is
225 the point of view of a perfect observer who knows the exact time course of the latent populations. Practically,
226 we are unable to know all the model variables, such as exposed and infectious populations inside and outside
227 hospitals; nonetheless, we can merely monitor positive reports by follow-up and mass-testing. In this study,
228 we verify whether these two kinds of positive reports reflect the latent infectious population, which is the
229 most resource-consuming and challenging social issue. Using regression analysis (see Materials and
230 Methods), we demonstrate that latent infectious populations can be predicted from daily positive reports of
231 follow-up and mass-testing (Fig. 6A to C). These results suggest that the infectious population is not simply
232 proportional to the sum of positive reports of follow-up and mass-testing; nevertheless, they are proportional
233 to their weighted sum (Fig. 6D). There are cases in which either weights can be negative, depending on the
234 model parameters. We found that the weight for positive reports of follow-up testing was negative with high
235 positive predictive values. This is because the negative weight of P_i acts in a repressive manner to estimate
236 the latent number of infectious people, reflecting a low positive predictive value (Fig. 6D).

237

238 Discussion

239 We develop a testing-SEIRD model to consider two discrete populations inside and outside hospitals, impact
240 of testing strategy (follow-up testing [f], and mass-testing [m]), and testing characteristics (sensitivity [Se]
241 and specificity [Sp]) on three variables (i.e., the number of maximum positive tests, maximum
242 hospitalizations, and cumulative deaths (Fig. 1)). By simulating the model with parameters, which describe
243 the early stage of the COVID-19 Alpha variant pandemic, we demonstrate that the optimal and the worst
244 testing strategies are subject to limited medical resource (Fig. 4). In addition, we highlight the possibility that
245 the infectious population can be predicted by a weighted sum of positive reports from follow-up and mass
246 testing (Fig. 6).

247

248 *Comparison with previous models*

249 There are several models of infectious dynamics, such as SIR [26] SEIRD models, and their
250 alternatives, which have been widely used for policy making through model simulation [1,27–34]. However,
251 some of the previous models do not include the hospital compartment, [28,33,35–37] and other models, even
252 with hospital compartments, do not consider the testing strategy and testing characteristics [30,38]. They
253 cannot address how the testing strategy and testing characteristics affect the number of deaths. Consequently,
254 we develop the testing-SEIRD model by introducing new factors: the hospital compartment, testing strategy,
255 testing characteristics, and medical resource to the previous SEIRD model (Fig. 2-4). The testing-SEIRD
256 model generalizes the classical SEIRD model, and it can be equivalent to the classical SEIRD model if the
257 testing strategy is removed ($f=0, m=0$).

258

259 *Model prediction*

260 Our model has three advantages. First, the testing-SEIRD model provides the best testing strategy
261 for situations. The model provides heatmaps of the number of the three variables in the space of the testing
262 strategy (Fig. 4). These heatmaps indicate the best direction as shown in the blue region in Fig. 4. This
263 corresponds to the settling of infections using the shortest path. Second, the testing-SEIRD model can predict
264 the optimal and worst strategies, considering the limited medical resource and ratios for the testing costs (Fig.
265 4). Because the total medical resource and testing costs depend on countries, our model offers the best
266 testing strategy unique to each country. Third, the testing-SEIRD model demonstrates that the latent number
267 of infectious populations can be predicted from daily positive reports of the follow-up and mass-testing (Fig.
268 6).

269

270 *Validity of model components*

271 Here, we discuss the validity of the model components, which previous models do not have. First, we focus
272 on the transition from E_o to E_s (Fig. 1). We assume that the hospitalization of the exposed population is
273 induced by the follow-up testing. Populations that are just exposed before developing symptoms do not take

274 the tests themselves. They test only when urged by the follow-up. Second, related to the transition from I_1 to
275 I_2 , we assume that the hospitalizations of the infectious population are induced by the mass-testing, which is
276 defined as a person with symptoms. Considering our model, we address the rate of mass-testing as a
277 modifiable parameter because the rate depends on the volume of the tests, such as polymerase chain reaction
278 (PCR) and the degree of social penalty if it is positive. Third, we consider the transition from E_1 to S_1 and E_2
279 to S_2 . Regarding our model, all the exposed populations are not necessarily infected and some return
280 susceptible compared to the previous models which assume that all the exposed populations are destined to
281 be infected [28,30,32,33,35–41]. Consistent with our model, it is well known that some exposed populations
282 return to susceptible populations without developing symptoms. Finally, our model is not specific to the
283 Alpha variant, but is applicable to other VOCs, because the assumptions mentioned above about exposure,
284 infection and hospitalization processes are common in VOCs [8]. Taken together, new components
285 introduced into the testing-SEIRD model not only are consistent with the previous simulation model, but also
286 reflect and incorporate a practical point of view.

287

288 ***Validity of model parameters***

289 We used parameters from the previous reports before the Beta variant appeared in South Africa in
290 May 2020 [8] (Table 1) because the earlier reports are homogeneous Alpha variant data. After May
291 2020, the reports are an inhomogeneous mixture of multiple variants. We set sensitivity and specificity of
292 testing to 0.7 and 0.7 accordingly and the results were robustly guaranteed by a sensitivity analysis (Fig. 4).
293 As the incubation and infectious periods remain roughly stable in the VOCs, while the number of
294 reproductions and mortality rates vary among variants [8,12,14]. The number of reproductions, reinfection
295 [42] effects were robustly guaranteed by a sensitivity analysis of b and u (Fig. S1). Mortality was taken into
296 account in the model with d_1 and d_2 and these values are sensitivity analyzed (Fig. S2). a or the rate of
297 discharge from S_1 was robustly guaranteed by a sensitivity analysis (Fig. S3). Although these values are
298 based on the COVID-19 Alpha variant, our sensitivity analysis indicates that the testing-SEIRD robustly
299 generated the optimal and worst testing strategy for other VOCs having different parameters.

300

301 ***Future studies***

302 Considering the future perspectives of our model, first, our testing-SEIRD model simulates only a
303 single peak time course of infection. However, we observed multiple peaks of COVID-19 infection in many
304 countries [43]. To incorporate the multiple peaked dynamics, we must introduce the socio-psychological
305 effects caused by policies such as lockdown and social distancing. Second, our model assumes that all the
306 populations are homogeneous and do not address stratification based on attributes such as gender, age, social
307 activities, and comorbidities [44,45]. A future study should consider this perspective. Finally, our model
308 does not include the effects of vaccination. We are currently fighting the spread of COVID-19 using
309 messenger RNA (mRNA) vaccines. It seems we are getting successful results; however, we do not know the

310 duration of the effect of the vaccinations or acquired immunity and its effectiveness against VOCs [43,46,47].
311 Therefore, the tag-of-war model between vaccines and virus evolution remains elusive.
312

313 **Materials and Methods**

314 *Parameter set*

315 The parameters and initial conditions of the simulation are listed in Table 1A. We used parameters
316 based on the studies of the COVID-19 Alpha variant. The total population N was set to 1,000,000 according
317 to the United Nations Statistical Papers: The World's Cities in 2018, which mentioned that one in five people
318 worldwide lives in a city with more than one million inhabitants and the median value of inhabitants is
319 between 500,000 and one million [48]. Sensitivity Se and specificity Sp were both set to 0.7, which
320 correspond to those of the PCR for detecting COVID-19 (Table 1B) [28,39,49–51]. The values of b , g , r_h , r_o ,
321 and d_h are based on previous reports (Table 1C) [3,29–34,36–38,42]. The sum of u and g is the inverse of the
322 incubation period during the exposed state, which is reported to be five days (Table 1C) [31–33,41,50]. The
323 sum of r and d is the inverse of the infectious period during the infectious state, which is reported to be ten
324 days (Table 1D) [31,32,35,50].

325

326 *Definitions of reproduction numbers*

327 Considering Fig. 2, we computed the time courses of reproduction numbers inside and outside
328 hospitals: RN_h and RN_o .

$$329 \quad RN_h = \frac{1}{r_h + d_h} \cdot \frac{bS_h}{S_h + E_h + I_h} \cdot \frac{g}{u + g}, \quad (5.1)$$

$$330 \quad RN_o = \frac{1}{r_o + d_o} \cdot \frac{bS_o}{S_o + E_o + I_o + R_o + R_h} \cdot \frac{g}{u + g}. \quad (5.2)$$

331 Here, the first, second, and third factors in these equations indicate the average infectious period, infection
332 rate, and probability that the exposed state transits to the infectious state, respectively. The reproduction
333 number in the classical SEIRD model is defined in previous studies [1,27–34] as:

$$334 \quad RN = \frac{1}{r + d} \cdot \frac{bS}{S + E + I + R}. \quad (5.3)$$

335

336 **Acknowledgments**

337 We thank Tomohiko Takada M.D. (Ph.D.) and Yoshika Onishi M.D. (Ph.D.) for providing the basic concept of
338 clinical NNT. We thank Yoshiaki Yamagishi M.D. (Ph.D.), Tomokazu Doi M.D. (Ph.D.), and Tatsuyoshi Ikenoue
339 M.D. (Ph.D.) for polishing early manuscript. We also thank Prof. Hiroshi Nishiura for providing the fundamental
340 knowledge of infectious disease modelling by organising a summer boot camp in 2014.

341

342 **Funding**

343 This study was partly supported by the Cooperative Study Program of Exploratory Research Centre on Life and
344 Living Systems (ExCELLS) (program Nos.18-201, 19-102, and 19-202 to H.N.), a Grant-in-Aid for
345 Transformative Research Areas (B) [grant number 21H05170], a Grant-in-Aid for Scientific Research (B)
346 (21H03541 to H.N.) from the Japan Society for the Promotion of Science (JSPS).

347

348 **Ethics**

349 Any human or animal subjects are not involved in this manuscript.

350

351 **Data Availability**

352 All relevant data are within the study and its supporting information files.

353

354 **Code Availability**

355 All codes to reproduce the results of this study are hosted in Github at <https://github.com/bougtoir/testing-SEIRD>.

356

357 **Author Contributions**

358 O.T. and Y.I. conceived of the initial ideas. O.T. developed and implemented the method, processed, and analysed
359 the data, and wrote the initial draft of the manuscript. H.N. edited the initial draft of the manuscript and reviewed
360 the method. Y.I. supervised the project. All authors contributed to the final writing of the manuscript.

361

362 **Competing Interests**

363 The authors declare no competing interests.

364

365

References

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400


1. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. 2020 COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. *Journal of Advanced Research* **24**, 91–98. (doi:10.1016/j.jare.2020.03.005)
2. Kolifarhood G, Aghaali M, Saadati HM, Taherpour N, Rahimi S, Izadi N, Saeed S, Nazari H. 2020 Epidemiological and Clinical Aspects of COVID-19; a Narrative Review. *Archives of Academic Emergency Medicine* **8**, 41.
3. Johns Hopkins Coronavirus Resource Center. In press. COVID-19 Map - Johns Hopkins Coronavirus Resource Center. See <https://coronavirus.jhu.edu/map.html> (accessed on 21 May 2020).
4. Our world in Data. In press. GitHub - owid/covid-19-data: Data on COVID-19 (coronavirus) cases, deaths, hospitalizations, tests • All countries • Updated daily by Our World in Data. See <https://github.com/owid/covid-19-data> (accessed on 31 March 2022).
5. Centers for Disease Control and Prevention. 2021 COVID Data Tracker, Centers for Disease Control and Prevention. See <https://covid.cdc.gov/covid-data-tracker/#datatracker-home> (accessed on 31 March 2022).
6. World Health Organization. In press. Coronavirus disease 2019 (COVID-19) Situation Report – 46.
7. World Health Organization. 2020 Laboratory testing strategy recommendations for COVID-19. See https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-eng.pdf.
8. World Health Organization (WHO). In press. tracking-SARS-CoV-2-variants. See <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>.
9. Joebges S, Biller-Andorno N. 2020 Ethics guidelines on COVID-19 triage - An emerging international consensus. *Critical Care* **24**, 1–5. (doi:10.1186/s13054-020-02927-1)
10. Yan Bai, MD Lingsheng Yao, MD TaoWei, MD Fei Tian, MD Dong-Yan Jin, PhD Lijuan Chen, PhD MeiyunWang, MD P. 2020 Letters Presumed Asymptomatic Carrier Transmission of COVID-19. (doi:10.1001/jama.2020.2565)
11. Al-Sadeq DW, Nasrallah GK. 2020 The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: A systematic review. *International Journal of Infectious Diseases* **98**, 372–380. (doi:10.1016/j.ijid.2020.06.098)
12. Mallett S *et al.* 2020 At what times during infection is SARS- CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. *BMC Med* **18**, 1–17. (doi:doi:10.1186/s12916-020-01810-8)
13. Yukari C. Manabe M, Joshua S. Sharfstein M, Katrina Armstrong M. 2020 The Need for

- 401 More and Better Testing for COVID-19. (doi:10.1001/jama.2020.21694)
- 402 14. Rhee C, Kanjilal S, Baker M, Klompas M. 2021 Duration of Severe Acute Respiratory
403 Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue
404 Isolation? *Clinical Infectious Diseases* **72**, 1467–1474. (doi:10.1093/cid/ciaa1249)
- 405 15. Wilson E, Donovan C v, Campbell M. 2020 Multiple COVID-19 Clusters on a University
406 Campus —. *MMWR Morb Mortal Wkly Rep* **69**, 1416–1418.
- 407 16. Id VB, Mallein B. 2021 Group testing as a strategy for COVID-19 epidemiological
408 monitoring and community surveillance. *PLoS Computational Biology* **17**, 1–25.
409 (doi:10.1371/journal.pcbi.1008726)
- 410 17. Organisation for Economic Cooperation and Development. 2020 Testing for COVID-19:
411 A way to lift confinement restrictions. See [https://read.oecd-](https://read.oecd-ilibrary.org/view/?ref=129_129658-l62d7lr66u&title=Testing-for-COVID-19-A-way-to-lift-confinement-restrictions)
412 [ilibrary.org/view/?ref=129_129658-l62d7lr66u&title=Testing-for-COVID-19-A-way-to-](https://read.oecd-ilibrary.org/view/?ref=129_129658-l62d7lr66u&title=Testing-for-COVID-19-A-way-to-lift-confinement-restrictions)
413 [lift-confinement-restrictions](https://read.oecd-ilibrary.org/view/?ref=129_129658-l62d7lr66u&title=Testing-for-COVID-19-A-way-to-lift-confinement-restrictions).
- 414 18. Signorini SG, Brugnoli D. 2021 Less is more : an ecological and economic point of view
415 on appropriate use of lab testing for COVID patients. *Bioanalysis* , 7–9. (doi:10.4155/bio-
416 2021-0064)
- 417 19. Centers for Disease Control and Prevention. 2020 Overview of testing for SARS-CoV-2
418 (COVID-19). See [https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html)
419 [overview.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html). Accessed 29 August 2020.
- 420 20. Id DRB, Bish EK, El-hajj H, Aprahamian H. 2021 A robust pooled testing approach to
421 expand COVID-19 screening capacity. *PLoS ONE* , 1–15.
422 (doi:10.1371/journal.pone.0246285)
- 423 21. Japanese society of pediatrics. In press. Thought on COVID-19 testing. See
424 http://www.jpeds.or.jp/modules/activity/index.php?content_id=329 (accessed on 21 May
425 2020).
- 426 22. World Health Organization. In press. WHO Director-General’s opening remarks at the
427 media briefing on COVID-19 - 16 March 2020. See [https://www.who.int/director-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---16-march-2020)
428 [general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---16-march-2020)
429 [on-covid-19---16-march-2020](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---16-march-2020) (accessed on 21 May 2020).
- 430 23. Godlee F. 2020 The burning building. *The BMJ* **368**, 2020. (doi:10.1136/bmj.m1101)
- 431 24. Peto J. 2020 Covid-19 mass testing facilities could end the epidemic rapidly. *The BMJ* **368**,
432 110110. (doi:10.1136/bmj.m1163)
- 433 25. World Health Organization. 2021 COVID-19: Laboratory and diagnosis.
- 434 26. Phelan. 2018 Mathematical models to characterize early epidemic growth: A Review
435 Gerardo. *Physiol Behav* **176**, 139–148. (doi:10.1016/j.pprev.2016.07.005.Mathematical)
- 436 27. Roguski KM *et al.* 2019 Estimates of global seasonal influenza-associated respiratory
437 mortality: a modelling study. *The Lancet* **391**, 1285–1300. (doi:10.1016/S0140-


- 438 6736(17)33293-2)
- 439 28. Fang Y, Nie Y, Penny M. 2020 Transmission dynamics of the COVID-19 outbreak and
440 effectiveness of government interventions: A data-driven analysis. *J Med Virol*
441 (doi:10.1002/jmv.25750)
- 442 29. Tang B, Bragazzi NL, Li Q, Tang S, Xiao Y, Wu J. 2020 An updated estimation of the risk
443 of transmission of the novel coronavirus (2019-nCov). *Infect Dis Model* **5**, 248–255.
444 (doi:10.1016/j.idm.2020.02.001)
- 445 30. Kucharski AJ *et al.* 2020 Early dynamics of transmission and control of COVID-19: a
446 mathematical modelling study. *The Lancet Infectious Diseases* **20**, 553–558.
447 (doi:10.1016/S1473-3099(20)30144-4)
- 448 31. Backer J, Klinkenberg D, Wallinga J. 2020 The incubation period of 2019-nCoV infections
449 among travellers from Wuhan, China. *Eurosurveillance* , 1–6.
450 (doi:10.1101/2020.01.27.20018986)
- 451 32. Bi Q *et al.* 2020 Epidemiology and transmission of COVID-19 in 391 cases and 1286 of
452 their close contacts in Shenzhen, China: a retrospective cohort study. *The Lancet*
453 *Infectious Diseases* **20**, 911–919. (doi:10.1016/S1473-3099(20)30287-5)
- 454 33. Kuniya T. 2020 Prediction of the Epidemic Peak of Coronavirus Disease in Japan, 2020. *J*
455 *Clin Med* **9**. (doi:10.3390/jcm9030789)
- 456 34. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, Yuan B,
457 Kinoshita R, Nishiura H. 2020 Incubation period and other epidemiological characteristics
458 of 2019 novel coronavirus infections with right truncation: A statistical analysis of publicly
459 available case data. *Journal of Clinical Medicine* **9**, 538.
460 (doi:10.1101/2020.01.26.20018754)
- 461 35. Joseph TW, Leung K, Leung GM. 2020 Nowcasting and forecasting the potential domestic
462 and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a
463 modelling study. *The Lancet* **395**, 689–697. (doi:10.1016/S0140-6736(20)30260-9)
- 464 36. Iwata K, Miyakoshi C. 2020 A Simulation on Potential Secondary Spread of Novel
465 Coronavirus in an Exported Country Using a Stochastic Epidemic SEIR Model. *Journal of*
466 *Clinical Medicine* **9**, 944. (doi:10.3390/jcm9040944)
- 467 37. Sun H, Qiu Y, Yan H, Huang Y, Zhu Y, Gu J, Chen S. 2021 Tracking Reproductivity of
468 COVID-19 Epidemic in China with Varying Coefficient SIR Model. *Journal of Data*
469 *Science* **18**, 455–472. (doi:10.6339/jds.202007_18(3).0010)
- 470 38. Rocklöv J, Sjödin H, Wilder-Smith A. 2021 COVID-19 outbreak on the diamond princess
471 cruise ship: Estimating the epidemic potential and effectiveness of public health
472 countermeasures. *Journal of Travel Medicine* **27**, 1–7. (doi:10.1093/JTM/TAAA030)
- 473 39. Lin L *et al.* 2020 Artificial Intelligence Distinguishes COVID-19 from Community
474 Acquired Pneumonia on Chest CT. *Applied Intelligence* **2019**, 1–5.

- 475 (doi:10.1148/radiol.2020200905)
- 476 40. Roda WC, Varughese MB, Han D, Li MY. 2020 Why is it difficult to accurately predict the
477 COVID-19 epidemic? *Infect Dis Model* **5**, 271–281. (doi:10.1016/j.idm.2020.03.001)
- 478 41. World Health Organization. 2020 China Joint Mission on Coronavirus Disease 2019
479 (COVID-19). *World health organization*. **2019**, 16–24. See
480 [https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-](https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19))
481 [coronavirus-disease-2019-\(covid-19\)](https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)) (accessed on 21 May 2020).
- 482 42. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ,
483 Dushoff J, Mlisana K, Moultrie H. 2022 Increased risk of SARS-CoV-2 reinfection
484 associated with emergence of Omicron in South Africa. *Science (1979)* **376**, 1–43.
485 (doi:10.1126/science.abn4947)
- 486 43. GISAID. In press. GISAID - Initiative. See <https://www.gisaid.org/> (accessed on 9 May
487 2021).
- 488 44. Shahid Z *et al.* 2020 COVID-19 and Older Adults: What We Know. *J Am Geriatr Soc* **68**,
489 926–929. (doi:10.1111/jgs.16472)
- 490 45. Thomas DM, Sturdivant R, Dhurandhar N v., Debroy S, Clark N. 2020 A Primer on
491 COVID-19 Mathematical Models. *Obesity* **28**, 1375–1377. (doi:10.1002/oby.22881)
- 492 46. Sharp TM *et al.* 2021 Antibody Persistence through 6 Months after the Second Dose of
493 mRNA-1273 Vaccine for Covid-19. *New England Journal of Medicine* **384**, 2257–2259.
494 (doi:10.1056/nejmc2023298)
- 495 47. Christian HH, Daniela M, Sophie MG, Kåre M, Steen E. 2020 Assessment of protection
496 against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark
497 in 2020: a population-level observational study Christian. *The Lancet* , 19–21.
498 (doi:10.1016/S0140-6736(21)00575-4)
- 499 48. United Nations. 2018 The World’s Cities in 2018: Data Booklet.
500 (doi:10.18356/C93F4DC6-EN)
- 501 49. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. 2020 Correlation of
502 Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A
503 Report of 1014 Cases. *Radiology*, 200642. (doi:10.1148/radiol.2020200642)
- 504 50. Long C *et al.* 2020 Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?
505 *European Journal of Radiology* **126**. (doi:10.1016/j.erad.2020.108961)
- 506 51. Lai S *et al.* 2021 Effect of non-pharmaceutical interventions to contain COVID-19 in
507 China. *Nature* **585**, 410–413. (doi:10.1038/s41586-020-2293-x.Effect)
- 508

A: SEIRD model



B: Our model




509

510 **Figure 1: Classical SEIRD and testing-SEIRD models**

511 (A) Classical SEIRD model: Susceptible population 'S' is exposed by infectious population 'I' at a rate
 512 proportional to the fraction of the infectious population. The exposed population 'E' become infectious 'I'. The
 513 infected population finally recovers 'R' or become dead 'D'. (B) Testing-SEIRD model: The population is
 514 divided into two subpopulations; inside and outside hospitals. The exposed 'E_o' and infectious population
 515 outside 'I_o' are hospitalised if evaluated as positive by testing. Susceptible population 'S_h' is left from the
 516 hospitals. The black lines indicate the transitions of populations, regardless of capacity effect. The blue lines
 517 indicate the transitions of the populations, considering the capacity effect. Transitions from both 'E_o' to 'E_h'
 518 and 'I_o' to 'I_h' are determined as hospitalised.

519



520

521 **Figure 2: Changes in components over time in the testing-SEIRD model**

522 Time-courses of (A) populations of all infectious states, irrespective of being inside and outside hospitals; (B)

523 Populations inside and outside hospitals and dead populations, irrespective of infectious states; (C)

524 Populations of all infectious states inside hospitals; (D) Populations of all infectious states outside hospitals;


525 (E) Daily reports of positive tests, hospitalisations, and deaths; (F) Time-courses of reproduction numbers

526 inside and outside hospitals, as described in Materials and Methods section.

527

528

529



530

531 **Figure 3: Impact of hospitalisations capacity on the three variables**

532 Time courses of (A) Daily reports of positive tests; (B) Daily reports of hospitalisations; (C) Daily reports of
 533 deaths with varying hospitalisation capacity. C/N indicates the capacity normalised to the total population.


534 Hospitalisation capacity dependencies of (D) Maximum positive reports; (E) Maximum hospitalisations; (F)

535 Cumulative deaths. Hospitalisation capacity-dependencies of (G) Peaks of daily reports of positive tests; (H)

536 Peaks of hospitalisations; (I) Peaks of daily deaths.

537


538



539

540 **Figure 4: Infectious spread based on the testing strategy**

541 The upper panels represent the number of (A) cumulative deaths, (B) maximum hospitalizations, and (C)
 542 maximum daily positive tests depending on the rates of follow-up and mass-testing. The three lines in these
 543 heatmaps represent the possible testing strategies subject to different total resource for testing with different
 544 ratios for the testing costs. The middle panels represent the numbers along the three lines in the heatmaps.
 545 The lower panels represent semilog-plots of the middle panels. $L=500$, $c_f=1$, $c_m=10$ in the green line, $L=300$,
 546 $c_f=1$, $c_m=5$ in the blue line, and $L=100$, $c_f=1$, $c_m=1$ in the orange line.



547

548

Figure 5: Infectious spread based on the testing properties


549

Number of (A) Cumulative deaths, (B) Maximum hospitalisations, and (C) Maximum daily positive tests


550

based on the sensitivity and specificity of the testing.


A: $(f, m) = (0.5, 0.01)$




B: $(f, m) = (0.5, 0.02)$



C: $(f, m) = (0.8, 0.02)$



D: Estimated weights for P_f and P_m



551

552

Figure 6: Prediction of infectious population from daily reports of positive tests

553

(A-C) The Green and orange lines indicate the simulated and predicted infectious populations (I_h and I_o) with

554

different testing strategies. The infectious populations are estimated by the linear regression as $w_f P_f + w_m P_m$,

555

where w_f and w_m indicate the weights and P_f and P_m indicate the daily positive reports of follow-up and mass-

556

testing, namely $f(1-Sp)$ and mSe , respectively. The weights are estimated by the least square method. (D)

557

The estimated weights for P_f and P_m are plotted, considering various combinations of ratios of the follow-up

558

cost to the mass-testing cost (P_f/P_m).

559

560

A		C							
Variable	Value	Reference	Model	b	g	r_h	r_c	d_h	d_s
S_h, E_h, I_h	1	Fang ²⁸	eSEIR	0.9 e-5 to e-6†	0.143	0.056	n/a	n/a	n/a
I_0	97	Tang ²⁹	n/a	2.1 e-8	0.126	n/a	0.14	1.78 e-5	n/a
S_0	999900	Kucharski ³⁰	eSEIR	n/a	0.156	n/a	n/a	n/a	n/a
E_0, R_0, R_c, D_h, D_s	0	Backer ³¹	n/a	n/a	0.143 to 0.33	n/a	n/a	n/a	n/a
		Bi Q ³²	n/a	n/a	n/a	n/a	n/a	n/a	n/a
		Kuniya ³³	SEIR	0.2 e-8†	n/a	n/a	n/a	n/a	n/a
		Linton ³⁴	n/a	n/a	0.2	n/a	n/a	n/a	n/a
		Iwata ³⁸	SEIR	n/a	0.167 to 0.208	0.13 to 0.417	n/a	n/a	n/a
		Sun ³⁷	vSIR	n/a	n/a	0.1	n/a	n/a	n/a
		Rocklöv ³⁸	SEIR	0.4 e-4 or 0.12 e-4†	0.2	n/a	n/a	n/a	n/a
		Roda ⁴⁰	SIR/SEIR	8.68 e-8	0.631	0.1	n/a	n/a	n/a

B		D	
Mode of test	Se	Reference	Infectious period
CT	0.98 ²⁸ , 0.97 ^{39,50} 0.8 to 0.9 ⁵¹ , 0.97 ⁵²	Kucharski ³⁰	2.9
		Backer ³¹	n/a
		Bi Q ³²	1.5
		Wu ³⁵	2.3
		Rocklöv ³⁸	10
		Lin ³⁹	2.3
PCR	0.71 ²⁸ , 0.846 ⁵²	WHO-China Joint ⁴¹	n/a
			5.2

561

562

563

564

565

566

567

568


569

Table 1: Variables and parameters in reports during the early stage of pandemic

(A) Initial values for variables and parameters and (B) Reported sensitivity and specificity of PCR and CT for detecting COVID-19. Cells expressed as n/a indicate that we cannot find the (C) reported transition parameters with models. Values with † are calculated from the original values for comparison. All the values have dimensions of [one/day]. We cannot find values or models for the cells expressed as n/a. The values with † equal original values divided by the total population involved. (D) Reported incubation period and infectious period. All values have dimensions of [day].

570

Supplementary Figures



571

572


Figure S1: Sensitivity analyses of parameters b and u on the number of cumulative deaths

573

Simulations were performed with different values of b and u .

574

575



576

577

Figure S2: Sensitivity analyses of d_o and d_h on the number of cumulative deaths

578

Simulations were performed with different values of d_o , d_h , where (d_o, d_h) of (0.01, 0.007) is a reference


579

standard, (0.01, 0.001) means advance in treatment, (0.01, 0.01) means futile treatment, and (0.001, 0.0007)

580

means reduction in overall mortality.

581



582
583
584
585

Figure S3: Sensitivity analyses of parameter a on the number of cumulative deaths
Simulations were performed with different values of parameter a .